Search Results - "BOLDRIN, Mark N"

XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study by Torgerson, Jarl S., Hauptman, Jonathan, Boldrin, Mark N., Sjöström, Lars

“…XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of…”
Get full text

Xenical in the prevention of diabetes in obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients by TORGERSON, Jarl S, HAUPTMAN, Jonathan, BOLDRIN, Mark N, SJÖSTRÖM, Lars

“…It is well established that the risk of developing type 2 diabetes is closely linked to the presence and duration of overweight and obesity. A reduction in the…”
Get full text

Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia by Lucas, Charles P, Boldrin, Mark N, Reaven, Gerald M

“…The objective of this study was to quantify the effectiveness of orlistat plus a reduced calorie diet on decreasing cardiovascular disease risk in obese…”
Get full text

Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults by Heymsfield, S B, Segal, K R, Hauptman, J, Lucas, C P, Boldrin, M N, Rissanen, A, Wilding, J P, Sjöström, L

“…Orlistat is a gastrointestinal lipase inhibitor that reduces dietary fat absorption by approximately 30%, promotes weight loss, and may reduce the risk of…”
Get more information

P-591: Effect of orlistat in patients with hypertension and either high or normal fasting insulin levels by Reaven, Gerald M., Segal, Karen R., Hauptman, Jonathan, Boldrin, Mark N., Lucas, Charles P.

“…All 214 subjects with elevated blood pressure (BP)(≥140/≥90 mmHg) were selected from the total pool of overweight or obese individuals who completed one year…”
Get full text

Effect of orlistat in patients with hypertension and either high or normal fasting insulin levels by Reaven, Gerald M, Segal, Karen R, Hauptman, Jonathan, Boldrin, Mark N, Lucas, Charles P

Get full text

Orlistat Reduces Body Weight and Cardiovascular Disease Risk Factors in Obese Men and Women with Type 2 Diabetes by HOLLANDER, PRISCILLA, LUCAS, CHARLES, HAUPTMAN, JONATHAN, BOLDRIN, MARK N, SEGAL, KAREN R

Get full text

Orlistat in the long-term treatment of obesity in primary care settings by Hauptman, J, Lucas, C, Boldrin, M N, Collins, H, Segal, K R

“…To evaluate the long-term efficacy and tolerability within primary care settings of orlistat, a gastrointestinal lipase inhibitor, for the treatment of…”
Get full text